Maryland Secures $4.5 Million Settlement with EpiPen Manufacturer Mylan

Maryland Attorney General Anthony G. Brown announced a significant settlement amounting to $4.5 million with Mylan Inc., the manufacturer of the EpiPen. This agreement aims to address concerns regarding anticompetitive practices that impacted the cost, marketing, and accessibility of the life-saving epinephrine auto-injector. The settlement is expected to bring financial relief and improved access for Maryland families who rely on this medication for severe allergic reactions.

The EpiPen is an essential emergency treatment for anaphylaxis, a potentially fatal allergic reaction that affects millions of Americans, including a substantial number of Maryland residents. These individuals depend on the EpiPen to manage severe allergies to common triggers such as foods, insect stings, and medications. The investigation, which Maryland joined in 2024, focused on allegations that Mylan had engaged in tactics to prevent lower-cost generic versions of the EpiPen from reaching the market, thereby maintaining its monopoly and increasing prices. After nearly two years of scrutiny and negotiations, a resolution has been reached.

Maryland’s inquiry identified specific actions taken by Mylan to preserve its market dominance. These included the formation of exclusionary contracts with pharmacy benefit managers, which effectively barred generic competitors. Additionally, Mylan allegedly filed patent lawsuits against competing products, later entering into “pay-for-delay” settlements, and lodged unsubstantiated concerns with the Food and Drug Administration regarding generic EpiPen alternatives to impede their availability and adoption.

Under the terms of the settlement, the State of Maryland will receive $4.5 million. These funds are earmarked for programs that will directly benefit Maryland residents, including initiatives focused on consumer protection and strengthening antitrust enforcement within the state. Beyond the financial remuneration, Mylan has committed to several measures designed to assist Maryland families, patients, and healthcare institutions. Among these is an increase in the co-pay coupon for the authorized generic version of the EpiPen, from $25 to $40. Furthermore, Mylan has agreed to enhance access to EpiPens for vulnerable populations within Maryland. This agreement resolves all claims pertaining to EpiPen pricing and competition within the state, and Maryland will continue its involvement in broader efforts addressing anticompetitive conduct within the pharmaceutical industry.

Article by Mel Anara, based upon information from the Maryland Attorney General.

---